The MAPK MEK/ERK pathway is often upregulated in cancer cells and represents an attractive target for development of anticancer drugs. Only few data concerning the specific functions of ERK1 and 2 are reported in the literature. In this report, we investigated the specific role of ERK1 and 2 in liver tumor growth both in vitro and in vivo. DNA synthesis and cells in S phase analysed by flow cytometry, correlated with strong inhibition of Cdk1 and cyclin E levels, are strongly reduced after exposure to the MEK inhibitor, U0126. We obtained a significant reduction of colony formation in soft agar assays and a reduction in the size of tumor xenografts in nude mice treated with U0126. Then, we could specifically abolished ERK1 or 2 expression by small-interfering RNA (siRNA) and demonstrated that ERK2 knockdown but not ERK1 interferes with the process of replication. Moreover, we found that colony formation and tumor growth in vivo were significantly inhibited by targeting ERK2 using stable chemically modified siRNA. Taken together, our results emphasize the importance of the MEK/ERK pathway in liver cancer cell growth in vitro and in vivo and argue for a crucial role of ERK2 in this regulation.
Introduction
Neoplasia is characterized by deregulated cell growth, survival and motility. Among the signaling pathways involved in these regulations, the MAPK MEK/ERK cascade seems to be a major component implicated in these biological processes (including proliferation, apoptosis and differentiation). Therefore, both enzymes of the cascade are considered attractive targets for cancer therapy. The ERK1/2 signaling pathway has been implicated in the regulation of both G 1 /S and G 2 /M transitions and mitosis in somatic cells. Disruption of ERK2 locus leads to embryonic lethality early in mouse development after the implantation stage (Saba-El-Leil et al., 2003) , whereas ERK1 mice are viable and fertile (Pages et al., 1999) , arguing for different roles of each kinase or a threshold of total ERK activity for viability. The lack of compensation of ERK2 deficiency by ERK1 raises the possibility that ERK2 could be specific in the developing embryo.
In addition, studies using pharmacological inhibitors of MEK (Alessi et al., 1995; Dudley et al., 1995) or activated MAPK phosphatase 1, a negative regulator of MEK (Brondello et al., 1995) , significantly altered the ability of these cells to proliferate in response to growth factor stimulation. A number of pharmacological agents have been described to inhibit MEK/ERK signaling in mammalian cells including PD098059, U0126 and CI-1040 (Wang et al., 2007) . A drug-targeting ERK activity decreases the incidence of colon carcinoma development in vivo (Sebolt-Leopold et al., 1999) . In a recent report, a novel orally active MEK inhibitor, PD184161, has been tested on hepatocellular carcinoma (HCC) xenografts and induced partial antitumoral effects in vivo (Klein et al., 2006) . PD184161 significantly suppressed tumor engraftment and initial growth but established tumors were not significantly affected. Validation of inhibitors of the MAPK pathway as anticancer therapeutics has been long awaited and CI-1040 became the first MEK inhibitor moved into a clinical trial (Wabnitz et al., 2004; Lorusso et al., 2005) . In addition, recent studies suggest that the antitumor activity of sorafenib in HCC models may be attributed to direct effects on tumor cell proliferation/survival in a MEK-dependent and -independent manners (Liu et al., 2006) . Other data strongly support the role of the MEK/MAPK pathway in the resistance of breast cancer cells to gefitinib and provide the rationale for novel therapeutic approaches based on combinations of signal transduction inhibitors (Normanno et al., 2006) . Some recent studies have been conducted on MEK/ERK pathway by RNA interference (RNAi) in tumor cell lines suggesting a specific role of each isoform (ERK1/2) to contribute to a regulated cell cycle, motility and apoptosis progression (Vantaggiato et al., 2006; Bessard et al., 2007) . Dominant-negative forms of ERK, and also ERK antisense nucleotides, inhibited proliferation of NIH 3T3 fibroblasts (Pages et al., 1993) .
In FT210 cells, ERK1 depletion caused cell-cycle arrest at G 2 , whereas the loss of ERK2 induced arrest at G 1 (Liu et al., 2004) . In NIH 3T3, knockdown of ERK2 almost completely abolished normal and Ras-dependent cell proliferation. ERK1 probably affects the overall signaling output of the cell by antagonizing ERK2 activity (Vantaggiato et al., 2006) . Recently, we established that RNAi-mediated inhibition of ERK2 in human hepatocarcinoma cells led to strongly reduced cell motility . Moreover, in hepatoma cells, activation of nucleotide excision repair pathway through its leading gene ERCC1 was specifically inhibited by knockdown of ERK2 in G 1 phase (Andrieux et al., 2007) . In normal hepatocytes, we highlighted that DNA replication is regulated by an ERK2-dependent mechanism and ERK1 cannot rescue ERK2 deficiency. All these results suggest that targeting ERK2 by RNAi could be an attractive target for cancer therapy.
In the present study, we investigated the role of the MAPK cascade in proliferation and regulation of the cell cycle in two liver cancer cell lines: HCC cells (FAO) in vitro and a biliary epithelial cell line (FI) in vitro and in vivo. The results provide evidence that treatment of these cells by the chemical inhibitor U0126, led to inhibition of ERK activity with a G 1 cell-cycle arrest. Moreover, using stable RNAi, we assessed the consequence of silencing ERK2 on tumor cell proliferation. Our results emphasize the importance of the MEK/ERK pathway in tumor growth and argue for a crucial role of ERK2 in this regulation in vitro and in vivo.
Results

Proliferation of hepatocarcinoma cells is mediated by the MEK/ERK cascade
Rat hepatocarcinoma cells (FAO) were stimulated or not by 10% fetal calf serum (FCS) in presence or absence of the MEK inhibitor, U0126. We first observed, after serum stimulation, that ERK1/2 were transiently phosphorylated (Figures 1a and b) and second that ERK1/2 activation was completely abolished in presence of the MEK inhibitor (Figure 1b) . DNA replication was strongly inhibited in presence of MEK inhibitor (Figure 1c ). This inhibition is not toxic and reversible as DNA synthesis was restored after U0126 removal. We ascertained that MEK-inhibited cells did not progress in apoptosis because U0126 did not induce caspase-3/7 activity measured through the proteolytic DEVD-AMC cleavage (Figure 1d ).
Flow cytometry was used to assess the cell cycle phase distributions of the cells treated or not with U0126 ( Figure 1e ). Cells have been collected 30 h after stimulation by FCS in presence or absence of U0126 or 15 h after removal of the inhibitor (U0126 reversion 45 h). Cells stimulated by FCS exhibited a significant proportion in S phase (32.62%) whereas U0126 strongly decreased the proportion of cells in S phase (9.92%) and increased the proportion of cells in G 0 -G 1 phase and to a lesser extent in G 2 /M. We confirmed that the blockade is reversible because 15 h after U0126 removal, cells progressed in S phase (27.15%). All these results provide evidence that the MAPK cascade MEK/ERK is mostly involved in S phase progression of hepatocarcinoma cells.
In primary culture of normal hepatocytes, expression of Cdk1, one marker of G 1 /S phase transition, is regulated by the MEK/ERK pathway (Albrecht et al., 1993; Rescan et al., 2001; Huynh et al., 2003) . Therefore, we looked at the regulation of this protein in transformed FAO cells and showed that Cdk1 expression was significantly blocked when cells were treated with U0126 ( Figure 1b) . Another marker of progression through S phase, cyclin E, showed the same MAPK-dependent regulation.
ERK2 is required for DNA replication
To estimate the specific role of ERK1 and 2 in hepatoma cell cycle replication, MAPK inhibition was performed by siRNA. At 72 and 96 h after transfection, the siERK2 inhibited protein expression by 85±5% compared with control transfection experiments. Moreover, the level of phospho-ERK2 was markedly reduced in these cells. ERK1 expression/phosphorylation was not affected showing the specificity of this inhibition for ERK2. The decrease in ERK2 expression/phosphorylation correlated with a decrease of Cdk1 expression. Interestingly, a decrease in DNA synthesis (50 and 20%, 48-72 h and 72-96 h, respectively, after transfection) has been obtained (Figure 2a ), indicating that ERK2 contributes at least partly, to the replicating property of the pathway.
We targeted ERK1 by the same way. Western blot analysis showed a fall of 80% in ERK1 expression, without affecting ERK2, and a strong decrease of ERK1 phosphorylation 72 and 96 h after transfection (Figure 2b ). ERK1 knockdown had no effect on Cdk1 expression and DNA replication was not affected showing that ERK1 is dispensable for full DNA synthesis as previously demonstrated in normal wild-type (wt) and ERK1 À/À hepatocytes .
Inhibition of MEK/ERK cascade activation acts on tumor cell growth in vivo To study the role of MEK/ERK in the regulation of the proliferation of transformed liver cells in vivo, we analysed this regulation in a highly tumorigenic cell line. Indeed, FI cells are able to grow in soft agar and give tumors in vivo after subcutaneous injection in mice. First, we confirmed the transformed phenotype of the FI cells by looking at colony formation in soft agar ( Figure 3a) . Then, the MEK inhibitor was added or not to cell culture 1 h prior FCS stimulation (Figure 3b ). We performed dose-response experiments in presence of U0126 (Figure 3c) . A high to a complete inhibition of ERK phosphorylation was obtained in presence of 10 and 50 mM, respectively. Moreover, phosphorylation of p38 was never affected by U0126 treatment, showing the absence of cross talks between MEK/ERK and p38 ERK2 targeting inhibits tumor growth A Bessard et al pathways ( Figure 3c ). Then, results evidenced that replication of FI cells was regulated by the MAPK cascade ( Figure 3d ), and a dose-response inhibition was obtained with a complete inhibition at 50 mM. We confirmed this role of MEK/ERK with the analysis of colony formation in presence of U0126 ( Figure 3e ). Indeed, the MEK inhibitor induced a strong inhibition on the ability of FI cells to form colonies in soft agar. The promising finding that U0126 strongly inhibited ERK1/2 activation, replication and colony formation in vitro prompted us to investigate its effect on tumor formation in nude mice. We analysed, first, the tumorigenicity of FI cells in vivo. Rapidly, 2-3 days after inoculation, mice developed solid spheroid tumors. Thus, 20 mm sections of tumors confirmed the presence of DiA-labeled cells (Figure 4a ).
Second, we tried to determine whether intraperitoneal injections of U0126 could potentially inhibit tumor engraftment and growth (Figure 4b ). At 3 h after cell injection subcutaneously, mice were treated daily with U0126 (10.5 mg/kg) or solvent control (DMSO) by intraperitoneal injection. In control experiment, tumor sizes were constant or slightly increase all over the kinetic. At the opposite, in all U0126 experiments, engraftment and early tumor growth were significantly decreased. Furthermore, a 60-70% reduction in the volume of tumors treated with U0126 was obtained 9 days after injection and thereafter. No treatment-related deaths of mice or toxicity were associated with U0126 or dimethyl sulfoxide (DMSO) injections. Western blot analysis of tumors indicated that U0126 induced a decrease in ERK1/2 phosphorylation (Figure 4c ). Moreover, Cdk1 expression was also strongly reduced in U0126-treated mice confirming lower S phase entry in MAPK-inhibited tumor xenografts.
Our results showed that inhibition of tumor growth was reversible and 3 days after U0126 removal, an increase of tumor growth started to be observed (Figure 4d ). Moreover, 10 days after the beginning of reversion experiments (Figure 4e , right), ERK1/2 were phosphorylated and Cdk1 expressed in tumors, confirming the reversion of the U0126 treatment (Figure 4e , left).
Specific ERK2 targeting by RNA interference inhibits tumor growth in vivo To assess the role of ERK2 in tumor cell growth in vivo, FI cells were transfected with siRNA directed against ERK2 (ERK2 D1 and its mutated control ERK2 D1m) and two others sequences against ERK2 that have been chemically modified (ERK2 Stab1 and 2, and their mutated control, controls 1 and 2). These locked nucleic acid (LNA) contain a methylene bridge connecting the 2 0 oxygen of the ribose with the 4 0 carbon. The bicyclic structure locks the furanose ring of the LNA molecule in a 3 0 -endo conformation, thereby structurally mimicking the standard RNA monomers. Western blot analysis (Figure 5a ) showed the high efficiency of ERK2 silencing 2, 4 and 6 days after transfection. Quantification studies of ERK2/PCNA indicated that ERK2 inhibitions were improved (92±5% of inhibition) when cells have been transfected with LNA sequences (ERK2 Stab1 and 2) as compared to unmodified sequence (ERK2 D1; 40±3% of ERK2 inhibition), 144 h after transfection. No significant differences could be noticed between the two chemically modified sequences and no changes with all control mutated sequences. In parallel, we looked at cell cycle markers expressions of cyclin D1 (Figure 5a ) and Cdk1 (Figure 5b ), two markers which are expressed, respectively, at late G 1 and S phase in normal hepatocytes and in HCC (Albrecht et al., 1993 (Albrecht et al., , 1995 Ito et al., 1998; Rescan et al., 2001) . Our results showed that cyclin D1 inhibition was partially inhibited in transfected cells. Moreover, Cdk1 expression significantly dropped 48 and 96 h after ERK2 silencing with ERK2 Stab1. Then, we determined the effects of ERK2 inhibition in the replication process (Figure 5c ). A decrease of 45 and 30% has been obtained with Stab1 and 2, respectively, showing that the reduction of ERK2 expression in FI cells could be related with a decrease of cell proliferation as determined in FAO cells. The effects of ERK2 silencing on cellular growth were evidenced by colony formation assays. Transfection with ERK2 RNAi induced a high decrease on the ability to form colonies: a 85 and 70% decrease for Stab1 and 2, respectively, but only 6% reduction for the non-LNA duplex (ERK2 D1), 13 days after seeding ( Figures 6A and B) . Control mutated sequences had no effect on the clonogenic capacity of the transfected cells.
The promising findings that inhibition of ERK2 expression by RNAi strongly inhibited colony formation led us to investigate its effect on tumor formation in nude mice, in vivo. ERK2 Stab1 siRNA and its mutated control were transfected, and 48 h after transfection, 2 Â 10 6 cells were inoculated subcutaneous into nude mice. Interestingly, cells transfected with Stab1 grew at lower rates than those transfected with the mutated control ( Figure 6C ) and a 90% reduction in the volume was measured 13 days postinjection. Finally, tumor cells were laser capture microdissected from sections of tumor using a Veritas LCM system (Arcturus) ( Figure 6D ). Proteins were extracted from the captured cells ( Figure 6D , c) and phospho-ERK1/2 analysed by immunoblotting ( Figure 6E ). Our results showed that the level of phospho-ERK2 was markedly reduced in tumors, 13 days after injection in nude mice of cells transfected with the ERK2 Stab1 siRNA and argued for a sustained inhibition of ERK2 after transfection with LNA.
Discussion
In the present report, we focused on the specific and critical role of ERK1 and 2 in the regulation of proliferation in vitro and tumorigenicity in vivo, using two experimental approaches: MEK inhibition by chemical inhibitor, ERK1 or 2 knockdown by siRNAs. The p44 ERK1 and p42 ERK2 have attracted intense research interest because of their involvement in the regulation of cell proliferation and survival (Pages et al., (c) ERK1/2 (P-ERK) and p38 (P-p38) activations were analysed 0.5 h after fetal calf serum (FCS) stimulation in presence of increasing concentrations of U0126 (from 10 to 50 mM). (d) For DNA synthesis experiment, a dose-dependent inhibition was performed at the indicated times after U0126 treatment. (e) Cells were seeded in soft agar in presence or absence of U0126 (50 mM). MEK inhibitor or solvent control (dimethyl sulfoxide, DMSO) was renewed each day and colony formation was observed 2 and 7 days after seeding.
1993; Vantaggiato et al., 2006) . There is increasing evidence that this pathway is abnormally regulated in transformed cells and could be important in tumorigenesis and maintenance of liver tumor growth (Schmidt et al., 1997; Huynh et al., 2003) . In addition, we recently demonstrated that motility and invasiveness of hepatocarcinoma cells required MEK/ERK activation . In this work, we demonstrated the importance of the MEK/ERK pathway in cancer liver cells proliferation in vitro and in vivo and argued for a crucial role of ERK2 in this regulation.
First, proliferation have been analysed in vitro by targeting MEK with the chemical inhibitor, U0126. Our results confirm the importance of the MAPK ERK1/2 pathway in the regulation of proliferation of the two transformed hepatic cell lines analysed, similar to that previously described in normal rat and mouse hepatocytes (Talarmin et al., 1999; Fremin et al., 2007) . Moreover, this inhibition of proliferation and the blockade in G 1 /S phase are reversible and not toxic in agreement with a nonapoptotic engagement of MEK-inhibited cells as measured by terminal caspases activity. Similar observations were obtained in pancreatic cancer cells lines where MEK inhibition led to a cessation of cell proliferation accompanied by a G 0 -G 1 cell-cycle arrest without a significant short-term increase in apoptosis (Gysin et al., 2005) .
Much of the focus in the development of novel therapeutics has involved inhibitors of signal transduction molecules, in particular protein kinases (Arslan et al., 2006; Sebolt-Leopold and English, 2006) . MEKtargeted treatment has been studied in colon, pancreatic, breast or melanoma tumors (Sebolt-Leopold et al., 1999; Duesbery et al., 2001; Yeh et al., 2007; Haass et al., 2008) and recently in human HCC tumors (Klein et al., 2006) . Targeting MEK with PD184161, which has the obvious advantages of solubility and oral bioavailability, in vivo resulted in a significant delay in HCC tumor engraftment and inhibition of early tumor growth. In contrast, PD184161 was ineffective at suppressing established HCC tumor growth. This result is in agreement with the report showing that PD184352, an treatment with the inhibitor was stopped 10 days postinjection and tumor sizes were measured up to 10 days after inhibitor removal (that is, 19 days after injection) (d). (e) Homogenates were prepared from one tumor coming from U0126 treated mice 9 days after injection (left) and two individual tumors 10 days after inhibitor removal (19 days after injection) (right) and assessed by western blot analysis for phosphorylated ERK1/2, ERK1/2 and Cdk1 levels. All samples are from the same blot.
other orally MAPK inhibitor, could induce a stabilization of the disease without however causing neither a strong reduction nor the disappearance of the tumor (Hilger et al., 2002) . Interestingly, in our study, intraperitoneal injection of U0126 decreased tumor engraftment and growth. U0126 is highly specific (Davies et al., 2000) but it lacks the pharmaceutical properties needed to be a successful clinical candidate. Nonetheless, these compounds have been invaluable academic research tools for dissecting the MEK/ ERK pathway and have provided enormous insight into the importance of MAPK signaling in cancer (Sebolt-Leopold and Herrera, 2004) . Several MEK inhibitors have been developed with different properties (more active, highly potent, bioavailability, y) and hepatic tumor cells should be good targets for these inhibitors.
We intended to specifically inhibit ERK1 and 2 by RNAi and could demonstrate that ERK2 but not ERK1 is important in cell proliferation. We established that targeting ERK2 alone was able to partially block DNA replication whereas ERK1 inhibition had no effect in the two transformed cell lines analysed. Our results are consistent with recent results from our laboratory , showing that downregulation of ERK2 in rat and mouse hepatocytes (wt and ERK1 À/À ) is associated with an inhibition in DNA synthesis. In human HCC cells, we have underlined that downregulation of ERK2 by RNAi strongly reduced cell motility and invasiveness whereas ERK1 inhibition had no impact on hepatoma cell motility . Proliferation of thymocytes was also ascertained to be specifically dependent on ERK2 signaling through the DN4 stage of development (Fischer et al., 2005) . It has been recently suggested that ERK1 acts as a negative regulator of cell proliferation in fibroblasts by restraining ERK2-dependent signaling (Vantaggiato et al., 2006) . This model of competition is based on observations that inactivation of ERK1 by either genetic disruption or RNAi silencing increases the proliferation rate of fibroblasts, whereas knockdown of ERK2 expression dramatically inhibits cell proliferation. However, these findings are discrepant with observations showing no difference in the proliferation rate of ERK1-deficient embryonic fibroblasts (Pages et al., 1999) whereas RNAi silencing of ERK1 inhibited the proliferation of HeLa cells to the same extent as ERK2 silencing (Liu et al., 2004) . Recent studies emphasize this controversy (Sanjo et al., 2007) . Using B-cell-specifictargeted mice, Sanjo et al. show the absolute normal proliferation of B cells lacking ERK2, and propose that ERK1 compensate for the loss of ERK2. Lefloch et al. (2008) showed that ERK1 and 2 kinase activities are indistinguishable in NIH3T3 cells and proposed that erk gene dosage is essential and drive their apparent biological differences.
New RNAi-based screening will help to identify novel cancer-selective drugs targets. Among the numerous potential therapeutic applications of RNAi, the silencing of genes involved in the promotion or maintenance of tumor growth appears as a very attractive additional approach to conventional chemotherapy for cancer treatment (Leung and Whittaker, 2005) . However, few data have been published reporting the successful use of siRNA for gene silencing in developing tumors in vivo in rodent models systems (Aharinejad et al., 2004; Takei et al., 2004) . Indeed, the biggest obstacle to developing siRNA-based therapies is the delivery of the siRNA 
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A Bessard et al molecules to the target tissue. Experiments have been done in vivo including hydrodynamic injection of synthetic siRNA, delivery using lipid-based agents and various carriers such as atelocollagen and polyethyleneimine, and also local administration (Behlke, 2006) . In our study, we improved strength and effectiveness of inhibition in vivo with LNA chemical modifications of siRNA. LNAs showed extraordinary thermal stabilities when hybridized with DNA, RNA or LNA itself. Moreover, introduction of LNA into siRNA could result in significantly less off target-regulated genes (Elmen et al., 2005; Dahlgren et al., 2006; Mook et al., 2007) . In agreement with other reports (Braasch et al., 2003; Elmen et al., 2005; Mook et al., 2007) , we showed that our ERK2 LNA are substantially compatible with the siRNA machinery, exhibit improved biostability and enhance inhibition in vivo. Indeed, at least 15 days after transfection, phospho-ERK2 inhibition was observed with the ERK2 Stab1, in vivo. Our data strengthen the usefulness of LNA-modified siRNA as an effective tool in functional genomics and possible future therapeutics applications in vivo.
In summary, this study shows that silencing ERK2 is effective against a model of tumoral growth in nude mice. Importantly, the reduction and the blockade of tumor growth observed after effective silencing of endogenous ERK2, reported here, strongly supports its potential therapeutic application. Obviously, identification of new molecules like siRNA that could interfere with specific targeted protein kinase should provide better and more rational treatments of cancer, in association with conventional treatment such as chemotherapy and/or radiotherapy.
Materials and methods
Cell lines and treatments
Rat hepatoma cell line FAO (Reuber, 1961) was maintained in a mixture of 50% Ham's F12 and 50% NCTC 135, supplemented with penicillin (100 IU/ml), streptomycin (100 mg/ml), glutamin (100 mg/ml) and 10% of FCS. FI rat biliary epithelial cells were obtained from liver of 10-day-old Fischer (Morel-Chany et al., 1978) . FI cells were grown in Williams' E medium containing sodium carbonate (22 mg/ml), penicillin (100 IU/ml), streptomycin (100 mg/ml) and 7.5% of FCS. All cells were maintained at 37 1C under a humidified 5% CO 2 atmosphere.
Immunoblotting analysis
Total protein (30 mg) was resolved on a 10% polyacrylamide gel and transferred to nitrocellulose membranes for 1 h as previously described (Rescan et al., 2001) . Membranes were incubated overnight at 4 1C with the following primary antibody in Tris-buffered saline (pH 7,4): a-phospho-ERK1/ 2 and a-phospho-p38 (Thr180/Tyr182) (Cell Signaling, Saint Quentin en Yvelines, France); a-pan ERK1 (sc-94) and ERK2 (sc-154), a-cyclin E (sc-481) and a-HSC 70 (sc-7298) (Santa Cruz Biotechnology, Santa Cruz, CA, USA); a-PCNA (Dako, Trappes, France); a-cyclin D1 (Neomarkers, Westinghouse, CA, USA). Anti-Cdk1 is a polyclonal antiserum specifically directed against the C-terminal part of human p34 (Loyer et al., 1996) . Antigen-antibody complexes were visualized using the SuperSignal Ultra Chemiluminescent Substrate procedure (Pierce, Rockford, IL, USA). Densitometric analysis of the bands was performed using Bioprofil Bio-1D (Vilbert-Lourmat, Marne-La-Valle´e, France) software. Caspase activity assay Cells were lysed in the caspase activity buffer as previously described (Stennicke and Salvesen, 1997) . Caspase-mediated cleavage of substrate AMC was measured by spectrofluorometry (Molecular Devices, Wokingham, UK) at the excitation/ emission wavelength pair of 380/440 nm. The caspase activity was expressed in V max .
Flow cytometry cell-cycle analysis Cell-cycle phase distribution was determined by flow cytometry. Cells were plated at a density of 3 Â 10 5 cells per 35 mm diameter dishes and treated or not with MEK inhibitor, U0126 (Promega, Charbonnie`res, France) for indicated times. DNA stained with propidium iodide (CycleTest Plus DNA reagent kit, BD Biosciences, San Jose, CA, USA) was then quantitated through the FACScalibur flow cytometer. Each measurement was conducted on 10 000 events and analysed on Cell Quest and Modfit Mac V2 Softwares (BD Biosciences).
Transfection and small interference experiments
Cells were plated at the density of 3.5 Â 10 5 FAO cells or 2 Â 10 5 FI cells in 35 mm diameter dishes and after 24 h, transfected for 15 h, for FAO or 5 h for FI cell line according to manufacturer's recommendations with 200 ml OPTIMEM, 5 ml transfectine (Bio-Rad, Hercules, CA, USA), 5% FCS and 5 ml of 20 mM small-interfering RNA (siRNA).
Two siRNA against murin ERK2 (ERK2: 5 0 -GUGCUGUG UCUUCAAGAGC-3 0 ; control: 5 0 -GGUGCCAUGGAACA GGUUG-3 0 ) and two against murin ERK1 (ERK1: 5 0 -UCC AAGGGCUACACCAAAU-3 0 ; control. 5 0 -UGUUAUAGG CAUCCGAGAC-3 0 ) were established according to Elbashir et al. (2002) and purchased from Eurogentec (Seraing, Belgium).
Two LNA oligonucleotides against ERK2 (ERK2 Stab1 and 2) and their mutated control (controls 1 and 2) were kindly provided by Heike Lehrmann, Sigma-Aldrich (St Louis, MO, USA). These sequences contain two [2 0 -O, 4 0 -C methylene bridge] on the 5 0 end of the sense strand which restrict the flexibility of the ribofuranose ring and lock the structure into a rigid bicyclic formation.
Colony formation assay
Colony formation assay was determined by a two-layer agar system. Biliary epithelial cells were plated in a 35 mm diameter dishes at the density of 1.5 Â 10 5 cells per dish. Colonies were visualized daily. In U0126 experiments, cells were suspended in presence of 50 mM U0126 or DMSO (solvent control) (Sigma, St Louis, MO, USA) at a final concentration of 0.5%. Every day, U0126 or DMSO was added.
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Animals
Athymic female nude mice (SWISS, nu/nu, Iffa-Credo, L'Arbresle, France) were purchased from germ free at 2-3 weeks old. Mice were housed in microisolator units under controlled humidity and temperature, and 12 h light-dark cycle. Animals received a standard sterilizable laboratory diet (UAR, France). Experiments were carried out in accordance with French laws and regulations.
Primary tumor growth
Prior to injection, FI cells were labeled with a stable fluorescent dye molecule, DiA (Molecular Probes, Cergy Pontoise, France) at 10 mg/ml for 5 h at 37 1C. After washing to remove free DiA, cells were trypsinized for inoculation (U0126 experiments) or transfection (RNAi experiments). Biliary epithelial cells were injected subcutaneously, at the indicated times, into the tibia of nude mice. In the chemical experiments, 3 h after inoculation, mice were treated with U0126 (10.5 mg/kg) daily by intraperitoneal injection. The length and width of each tumor were measured every day by using a caliper. The following formula was used to calculate tumor volumes ¼ width 2 Â length/2. Mice were killed at the end of experiment. Tumors were immediately frozen in liquid nitrogen.
Laser capture microdissection Tumor cells were laser capture microdissected by using a Veritas LCM system (Arcturus) from fluorescent tumor sections. Microdissected samples were dropped by gravity into cap-tubes under microscope inspection. Total protein was extracted from the captured cells and analysed by immunoblotting.
Statistical analysis
Data are presented as means ± s.d. from at least three experiments. The statistical analyses were carried out using Student's t-test. A P-value o0.05 was considered as statistically significant.
Abbreviations cdk, cyclin-dependent kinase; ERK, extracellular signalregulated kinase; HCC, hepatocellular carcinoma; LNA, locked nucleic acid; MEK, mitogen-activated protein kinase; siRNA, small-interfering RNA.
